Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Primary Myelofibrosis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Hemoglobinuria, Paroxysmal 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 6Melphalan 5Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Antibodies 4Cyclophosphamide 3thymoglobulin 2Tacrolimus 2Methotrexate 2Cyclosporine 2Busulfan 2Antilymphocyte Serum 2Alemtuzumab 2merphos 1fludarabine 1Transplantation, Homologous 1Thiotepa 1Sirolimus 1Rituximab 1Observation 1Muromonab-CD3 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Drug Therapy 1Cyclosporins 1Basiliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × Basiliximab × Myeloid × Clear all
NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

Phase 2 Completed
17 enrolled 9 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡